Eikon Therapeutics prices upsized IPO at $18 per share

Eikon Therapeutics, Inc. (NASDAQ: EIKN) announced the pricing of its upsized initial public offering of 21,177,600 shares of common stock at $18.00 per share. The biopharmaceutical company granted underwriters a 30-day option to purchase up to an additional 3,176,640 shares at the same price.

The company expects gross proceeds of approximately $381 million from the offering, before deducting underwriting discounts, commissions and offering expenses. The figures do not include potential proceeds from the underwriters' option to purchase additional shares.

Eikon's common stock is scheduled to begin trading on the Nasdaq Global Select Market on February 5, 2026 under the ticker symbol "EIKN". The offering is expected to close on or about February 6, 2026, subject to customary closing conditions.

J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and Mizuho are serving as joint book-running managers for the offering. The Securities and Exchange Commission declared the company's Form S-1 registration statement effective on January 30, 2026.

Eikon describes itself as a late-stage clinical biopharmaceutical company focused on developing medicines for serious unmet medical needs. The company's initial focus is oncology, where it is advancing drug candidates targeting areas of high unmet need in large indications. Eikon also operates a technology platform that includes a proprietary single molecule tracking system for developing novel therapies.

The information is based on a company press release statement.

You May Also Be Interested In

• AMR Resources prices $250M IPO on Nasdaq at $10 per unit
• DBV Technologies refreshes ATM program with $150M ADS offering
• Cosmos Health buyback reaches 5.11 million shares at avg $0.2554